Cincinnati Pediatric Clinical Pharmacology Postdoctoral Training Program

辛辛那提儿科临床药理学博士后培训项目

• 批准号: 9547581
• 负责人: Alexander A Vinks
• 金额: $ 6.36万
• 依托单位: CINCINNATI CHILDRENS HOSP MED CTR
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-16 至 2021-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9547581
• 关键词: Childhood; Clinical Pharmacology; Training Programs; post-doctoral training

 DESCRIPTION (provided by applicant): The need for pediatric clinical pharmacology research and training has never been greater. The T32 Training Program in Pediatric Clinical Pharmacology at Cincinnati Children's Hospital Medical Center (CCHMC) is designed specifically to address this critical need. The program is based in the Division of Clinical Pharmacology, which is jointly a unit within the Department of Pediatrics and the University of Cincinnati, College of Medicine (UCCOM). This T32 Training Program also involves strong collaborations with the James L. Winkle College of Pharmacy and the Departments of Pharmacology & Cell Biophysics and Biomedical Informatics at the UCCOM. The program outlined in this renewal application draws on strong leadership and a diverse group of well-established faculty mentors actively involved in clinical pharmacology research representing 12 divisions within the Department of Pediatrics and 4 Departments at the University of Cincinnati. The program has strong institutional support and takes advantage of a variety of advanced technologies and resources within a uniquely collaborative environment. The T32 training program is innovative and well aligned with the objectives outlined in the program announcement as it: (1) has a focus in early and later phase studies in multiple and diverse pediatric populations through ongoing research collaborations with all major pediatric subspecialties; (2) involves the application and development of innovative quantitative methodologies such as physiologically based PK/PD modeling, systems pharmacology and quantitative modeling and simulation and in silico clinical trial design; (3) is embedded in the institutional and Academic Health Center's pharmacogenetic/genomics research and training endeavors of the Center for Pediatric Genomics; (4) is closely integrated with Bioinformatics and Health Services and Outcomes Research; (5) can rely on over ten years of experience as one of 13 sites of the Pediatric Pharmacology Research Unit (PPRU) network, and on one funding cycle as a successful training program. The program provides a unique training experience and has successfully opened new avenues to enlarge the pool of talented young clinical investigators with a career interest in pediatric therapeutics. The training program allows postdoctoral fellows to acquire a refined vision for applying state of the art principles of pediatrics clinical pharmacology to clinical research and evidence- based practice with the goal to improve therapeutics and health outcomes in children.

 描述（由申请人提供）：对儿科临床药理学研究和培训的需求从未如此之大。辛辛那提儿童医院医学中心（CCHMC）的T32儿科临床药理学培训计划专门针对这一关键需求而设计。该项目设在临床药理学部，该部门是儿科系和辛辛那提大学医学院（UCCOM）的联合单位。这个T32培训计划还涉及与詹姆斯L。温克尔药学院和UCCOM的药理学与细胞生物物理学和生物医学信息学系。本更新申请中概述的计划借鉴了强有力的领导和积极参与临床药理学研究的各种成熟的教师导师，代表了辛辛那提大学儿科系和4个系的12个部门。该计划拥有强大的机构支持，并在独特的协作环境中利用各种先进技术和资源。T32培训计划是创新的，与计划公告中概述的目标保持一致，因为它：（1）通过与所有主要儿科亚专科的持续研究合作，重点关注多个和不同儿科人群的早期和后期研究;（2）涉及创新定量方法的应用和开发，如基于生理学的PK/PD建模，系统药理学和定量建模和模拟以及计算机临床试验设计;（3）嵌入儿科基因组学中心的机构和学术健康中心的药物遗传学/基因组学研究和培训工作中;（4）与生物信息学和健康服务和成果研究紧密结合;（5）可以依靠十多年的经验，作为儿科药理学研究单位（PPRU）网络的13个网站之一，并在一个资金周期作为一个成功的培训计划。该计划提供了独特的培训经验，并成功地开辟了新的途径，以扩大有才华的年轻临床研究人员与儿科治疗的职业兴趣池。该培训计划使博士后研究员能够获得将儿科临床药理学的最新原理应用于临床研究和循证实践的精致愿景，目标是改善儿童的治疗和健康结果。